natgillin/translations-raw huggingface dataset:
immunreaktiveringssyndrom1
immune reactivation syndrome1
Immunrekonstitutionsinflammatorisk syndrom
Immune Reconstitution InflammatorySyndrome
immunrekonstitutionsinflammatorisk syndrom (IRIS) (lægemiddel) overfølsomhed
immune reconstitution inflammatory syndrome, (drug) hypersensitivity
immunrekonstitutionsinflammatorisk syndrom (IRIS) , (lægemiddel)overfølsomhed
immune reconstitution inflammatory syndrome, (drug) hypersensitivity
immunrekonstitutionsinflammatorisk syndrom (IRIS),
immune reconstitution inflammatory syndrome, (drug) hypersensitivity
immunrelaterede bivirkninger
immune-mediated adverse events
Immunrelaterede bivirkninger, som kan være svære eller livstruende, kan omfatte mave–tarmkanal, lever, hud, nervesystemet, det enokrine system eller andre organsystemer.
Immune-related adverse reactions, which can be severe or life-threatening, may involve the gastrointestinal, liver, skin, nervous, endocrine, or other organ systems.
Immunrelateret
Immune-related
Immunrelateret
Immune-related adverse reaction
Immunrelateret colitis anormaliteter bedres, og behandling med kortikosteroid er afsluttet
Immune-related colitis symptoms resolve, radiographic abnormalities improve, and management with corticosteroids is complete
Immunrelateret levertoksicitet
Immune-related hepatotoxicity
Immunrelateret nefritis eller nedsat nyrefunktion
Immune-related nephritis or renal dysfunction
Immunrelateret udslæt
Immune related rash
Immunrelateret udslæt
Immune-related rash
Immunrespons hos småbørn i alderen 12-14 måneder
Immune responses in toddlers aged 12-14 months
Immunrespons mod A/California/7/2009 (H1N1)v-lignende stamme
Immune response to A/California/7/2009 (H1N1)v-like
Immunrespons mod A/Netherlands/602/9 (H1N1)v-lignende stamme 1
1antigenically similar to A/California/7/2009 (H1N1)v-like
Immunrespons mod A/Netherlands/602/9 (H1N1)v-lignende stamme 1
Immune response to A/Netherlands/602/9 (H1N1)v-like1
Immunrespons mod A/Vietnam/1194/2004 (dag 42)
Immune response to A/Vietnam/1194/2004 (D42)
Immunrespons mod A/Vietnam/1203/2004 (H5N1)
Immune response against A/Vietnam/1203/2004 (H5N1)
Immunrespons mod en version af Celvapan indeholdende A/H5N1-vaccinestamme
Immune response against a version of Celvapan containing A/H5N1 vaccine strains
Immunrespons over for Gardasil 9 ved måned 7
Immune response to Gardasil 9 at month 7
Immunrespons over for Gardasil 9, når der anvendes en 2-dosis tidsplan hos personer mellem 9 til 14 år.
Immune Responses to Gardasil 9 using a 2-dose schedule in individuals 9 through 14 years of age
Immunrespons på Focetria H1N1v
Immune response to Focetria H1N1v
Immunrespons på homologe stammer [A/Vietnam/1194/2004 (H5N1) og A/turkey/Turkey/1/05 (H5N1)]
Immune response to Homologous Strains [A/Vietnam/1194/2004 (H5N1) and A/turkey/Turkey/1/05 (H5NI)]
Immunrespons på vaccination målt ved mikroneutraliserings- (MN-)analyse er på linje med resultater opnået med SRH.
Immune response to vaccination assessed by MicroNeutralisation (MN) assay is in line with results obtained with SRH.
Immunrespons på vaccination målt ved MN-analyse er lig resultater opnået med SRH.
Immune response to vaccination assessed by MN assay is similar to SRH results.
Immunrespons syndrom
Immune response syndrome
Immunresponsene på serotype 6A var statistisk signifikant større efter vaccination med Prevenar 13 end efter 23-valent pneumokok polysaccharidvaccine .
Immune responses to serotype 6A were statistically significantly greater following vaccination with Prevenar 13 than after 23-valent pneumococcal polysaccharide vaccine.
Immunresponserne på PRP-, PT- og FHA-antigener en måned efter 2 doser, givet ved 2 og 4 måneder, svarede til dem, der blev observeret en måned efter en 2-dosis priming, givet ved 3 og 5 måneder: anti- PRP-niveau ≥ 0,15 µg/ml blev observeret hos 73,0 % af individerne, anti-PT-vaccinerespons hos 97,9
The immune responses to PRP, PT and FHA antigens one month after 2 doses given at 2 and 4 months of age were similar to those observed one month after a 2-dose priming given at 3 and 5 months of age: anti-PRP titers ≥ 0.15 µg/ml were observed in 73.0% of individuals, anti-PT vaccine response in 97.9% of individuals and anti-FHA vaccine response in 98.6% of individuals.
Immunresponset efter boosterdosis i denne aldersgruppe var generelt sammenlignelig med det respons, der blev observeret efter boosterdosis hos børn, som havde fået primærprogrammet med tre doser, før de var 6 måneder gamle.
The immune responses after the booster dose in this age group were generally similar to those observed after the booster dose in infants who had been primed with 3 doses below 6 months of age.
Immunresponset over for Fluarix var tilfredsstillende.
The immune response to Fluarix was satisfactory.
Immunresponset på alle fire QIV- stammer var non-inferiort, når Prevenar 13 blev givet samtidig med QIV, sammenlignet med QIV givet alene.
The immune responses to all four QIV strains were noninferior when Prevenar 13 was given concomitantly with QIV compared to when QIV was given alone.
Immunresponset på vaccinen er ikke undersøgt i sammenhæng med genetisk polymorfi.
Immune responses to the vaccine have not been studied in the context of genetic polymorphism.
Immunresponset var sammenligneligt hos voksne og unge ved anvendelse af to-dosis-vaccinations- programmer administreret med et interval på en eller to måneder.
The vaccination schedules of two doses administered with an interval of one or two months showed similar immune responses in both adults and adolescents.
immunsuppresiva vil øges ved samtidig
immunosuppressants will be increased
Immunsuppressiv behandling inden behandling med TYSABRI
Immunosuppressant treatment prior to the use of TYSABRI
Immunsuppressiv behandling kan påvirke patienters respons over for vaccinationer.
Immunosuppressant therapy may affect response to vaccination.
Immunsuppressiva
Immuno-suppressive therapy
Immunsuppressiva
Immunosuppresants
Immunsuppressiva
Immunosuppressive agents
IMMUNSUPPRESSIVA
IMMUNOSUPPRESSIVES
Immunsuppressiva
Lipid lowering agents
IMMUNSUPPRESSIVA
NARCOTIC ANALGESICS
Immunsuppressiva
observed pharmacokinetic
IMMUNSUPPRESSIVA
Rash (11.6%)
Immunsuppressiva behandling
Immuno-suppressive therapy
Immunsuppressiva er blevet indgivet eksperimentelt til et lille antal patienter med henblik på at reducere eller forhindre udvikling af antistoffer mod alglucosidase alfa.
Immunosuppressive agents have been administered in experimental settings in a small number of patients, in an attempt to reduce or prevent the development of antibodies to alglucosidase alfa.
Immunsuppressiva kan påvirke respons på vaccinationer, der under behandling med tacrolimus kan vise sig mindre effektive.
Immunosuppressants may affect the response to vaccination and vaccination during treatment with tacrolimus may be less effective.
Immunsuppressiva metaboliseres via CYP3A4 (fx ciclosporin, tacrolimus, sirolimus)/efavirenz
Immunosuppressants metabolized by CYP3A4 (e.g., cyclosporine, tacrolimus, sirolimus)/Efavirenz
Immunsuppressiva metaboliseres via CYP3A4 (fx ciclosporin, tacrolimus, sirolimus)/efavirenz
Immunosuppressants metabolized by CYP3A4 (eg, cyclosporine, tacrolimus, sirolimus)/Efavirenz
immunsuppressiva midler vil øges ved
immunosuppressants will be increased
Immunsuppressiva reducerer kroppens respons på alt som synes ”fremmed” – inklusive transplanterede organer.
Immunosuppressants reduce the body’s response to anything that it sees as “foreign” – which includes transplanted organs.
immunsuppressiva vil øges ved samtidig
immunosuppressants will be increased
immunsuppressiva – tacrolimus, sirolimus, ciclosporin
immunosuppressants – tacrolimus, sirolimus, cyclosporine
immunsuppressiva, fordi
immunosuppressants should
Immunsuppressive lægemidler kan påvirke responset på vaccination, og vaccination under behandling med tacrolimus kan være mindre effektiv.
Immunosuppressants may affect the response to vaccination and vaccination during treatment with tacrolimus may be less effective.
Immunsuppressive lægemidler såsom ciclosporin, sirolimus eller tacrolimus (medicin til at forhindre afstødelse af organer efter transplantation): når De starter eller stopper med at tage Stocrin vil lægen kontrollere indholdet af det immunsuppressive lægemiddel i blodet, og det kan være nødvendigt at justere dosis.
Immunosuppressants such as cyclosporine, sirolimus, or tacrolimus (medicines used to prevent organ transplant rejection): when you start or stop taking Stocrin, your doctor will closely monitor your plasma levels of the immunosuppressant and may need to adjust its dose.
Immunsuppressive lægemidler såsom ciclosporin, sirolimus eller tacrolimus (medicin til at forhindre afstødelse af organer efter transplantation): når du starter eller stopper med at tage Efavirenz Teva vil lægen kontrollere indholdet af det immunsuppressive lægemiddel i blodet, og det kan være nødvendigt at justere dosis.
Immunosuppressants such as ciclosporin, sirolimus, or tacrolimus (medicines used to prevent organ transplant rejection): when you start or stop taking Efavirenz Teva, your doctor will closely monitor your plasma levels of the immunosuppressant and may need to adjust its dose.
Immunsupprimerede personer eller personer med et svækket immunforsvar må ikke håndtere denne vaccine.
Immunocompromised/immunosuppressed individuals must not be allowed to handle this vaccine.
Immunsupprimerende midler (fx ciclosporin, tacrolimus, sirolimus)
Immunosuppressants (e.g. cyclosporin, tacrolimus, sirolimus)
Immunsupprimerende midler (tacrolimus, cyclosporin, sirolimus)
Immunosuppressants (tacrolimus, cyclosporine, sirolimus)
immunsupprissiva vil øges ved samtidig
immunosuppressants will be increased
Immunsvar efter boosterinjektion
3.69 µg/ml).
Immunsy- stemet
Immune system disorders
Immunsygdomme der kan påvirke lunger, hud og lymfekirtler (viser sig hyppigst som sarkoidose)
Immune disorders that could affect the lungs, skin and lymph nodes (most commonly presenting as sarcoidosis)
immunsygdomme, såsom sarkoidose (udslæt, ledsmerter, feber), serumsygdom, betændelse i fedtvævet, angioneurotisk ødem (hævelse af læberne, ansigtet, svælget)
immune disorders such as sarcoidosis (rash, joint pain, fever), serum sickness, inflammation of the fat tissue, angioneurotic oedema (swelling of the lips, face, throat)
Immunsyste
Immune system
Immunsyste- met
Immune system disorders
Immunsystem
Immune system disorders
Immunsystem et
(including
Immunsystem et
Immune system
Immunsystemdefekt, som kan påvirke lunger, hud og lymfekirtler (såsom sarkoidose)
Immune disorders that could affect the lungs, skin and lymph nodes (such as sarcoidosis)
Immunsystemdefekt, som kan påvirke lunger, hud og lymfekirtler (såsom sarkoidose)
Immune disorders that could affect the lungs, skin and lymph nodes (such as sarcoidosis).
Immunsysteme
Immune
Immunsystemet
Body System
Immunsystemet
Endocrine Disorders
Immunsystemet
Eye disorders
Immunsystemet
hyperhidrosis
Immunsystemet
Immune
Immunsystemet
Immune system disorders:
Immunsystemet
Metabolism and nutrition disorders
Immunsystemet
Nervous system disorders
Immunsystemet
pancytopenia,
Immunsystemet
Psychiatric Disorders
Immunsystemet
Treatment regimen d
Immunsystemet (se Hud og subkutane væv)
Immune system disorders (see Skin and subcutaneous tissue disorders)
Immunsystemet Ikke almindelig Overfølsomhed
Immune system disorders Uncommon Hypersensitivity
Immunsystemet kan således danne antistoffer hurtigere, når det eksponeres for samme virus igen.
The immune system will then be able to produce antibodies more quickly when it is exposed to the virus again.
Immunsystemet kan således hurtigere danne antistoffer, når det udsættes for samme virus igen.
The immune system will then be able to produce antibodies more quickly when it is exposed to the virus again.
Immunsystemet Overfølsomhed*
Immune system disorders Hypersensitivity
Immunsystemet Udslæt, pruritus
Immune system disorders
Immunsystemet vil derefter kunne danne antistoffer hurtigere, hvis personen naturligt udsættes for de samme bakterier eller virus.
The immune system will then be able to produce antibodies quickly when the person is naturally exposed to the bacteria or viruses.
Immunsystemet vil derefter være i stand til hurtigere at danne antistoffer, når det eksponeres for samme virus igen.
The immune system will then be able to produce antibodies more quickly and in large numbers when it comes into contact with the virus again.
Immunsystemet vil efterfølgende blive i stand til at skelne proteinet fra det sygdomsforårsagende virus og danne antistoffer hurtigere, hvis det udsættes for sådanne vira.
In the future, the immune system will be able to recognise the protein from the disease-causing virus and produce antibodies more quickly when it is exposed to such viruses.
Immunsystemet vil efterfølgende være i stand til at danne antistoffer langt hurtigere, når barnet på naturlig vis eksponeres for bakterierne eller viraene.
The immune system will then be able to produce antibodies more quickly when the person is naturally exposed to the bacteria or viruses.
Immunsystemet vil efterfølgende være i stand til at danne antistoffer langt hurtigere, når personen på naturlig vis eksponeres for bakterierne eller viraene.
The immune system will then be able to produce antibodies more quickly when the person is naturally exposed to the bacteria or viruses.
Immunsystemet*
anaemia
Immunsystemet*
Immune system disorders
Immunsystemet**
Immune System Disorders
Immunsystemet6
Immune system disorders6
Immunsystemet:
Overdose
Immunsystemet: anafylaktiske reaktioner
Immune system disorders: anaphylactic reactions
Immunsystemet: Anafylaktiske reaktioner, overfølsomhed Nervesystemet: Feberkramper.
Immune system disorders: anaphylactic reaction, hypersensitivity Nervous system disorders: febrile convulsion
Immunsystemet: Angioødem og allergisk ødem (i de samlede fase III-studier var disse bivirkninger ikke almindelige (≥ 1/1.000 til < 1/100)).
Immune system disorders: Angioedema and allergic oedema (In the pooled phase III trials, these events were uncommon (≥ 1/1,000 to < 1/100)).
Immunsystemet: Angioødem og allergisk ødem (i de samlede fase III-studier var disse bivirkninger ikke almindelige (≥ 1/1.000 til < 1/100).
Immune system disorders: Angioedema and allergic oedema (In the pooled phase III trials, these events were uncommon (≥ 1/1,000 to < 1/100)).
Immunsystemet: Idiopatisk (eller trombotisk) trombocytopenisk purpura (flere blå mærker, blødning, nedsat antal blodplader, blodmangel og ekstrem svaghed)
Immune system disorders: Idiopathic (or thrombotic) thrombocytopenic purpura (increased bruising, bleeding, decreased platelets, anaemia and extreme weakness)
Immunsystemet: ikke almindelig: overfølsomhed
Immune system disorders: uncommon: hypersensitivity
Immunsystemet: Ikke kendt: Sjældne tilfælde af overfølsomhedsreaktioner som fx angioødem, udslæt og urticaria
Immune system disorders: Not known: cases of hypersensitivity reactions such as angioedema, rash, urticaria
Immunsystemet: Overfølsomhed
Immune system disorders: Hypersensitivity
Immunsystemet: Overfølsomhedsreaktioner herunder anafylaktiske/anafylaktoide reaktioner, bronkospasmer og urtikaria.
Immune system disorders: Hypersensitivity reactions including anaphylactic/anaphylactoid reactions, bronchospasm and urticaria.
Immunsystemet: Sarcoidose (områder med betændt væv over hele kroppen) og betændelse i skjoldbruskkirtlen
Immune system disorders: Sarcoidosis (areas of inflamed tissue occurring throughout the body), inflammation of the thyroid
Immunsystemet: Vogt-Koyanagi-Haradas syndrom (en sjælden sygdom karakteriseret ved tab af syn, hørelse og hudpigmentering, afstødelse af transplanteret lever eller nyre).
Immune system disorders: Vogt Koyanagi Harada disease – a rare disease characterised by loss of vision, hearing and skin pigmentation; liver and kidney transplant rejections
Immunsystemet§
Immune system disorders§
immunundertrykkende lægemidler (f.eks. ciclosporin, tacrolimus)
medicines to reduce the activity of the immune system (e.g. ciclosporin, tacrolimus)
immunundertrykkende midler, anvendes til at kontrollere kroppens immunrespons efter en transplantation, såsom:
immunosuppressants, used to control your body’s immune response after a transplant, such as:
immunundertrykkende midler, anvendes til at kontrollere kroppens immunrespons efter en transplantation, såsom:
immunosupressants, used to control your body’s immune response after a transplant, such as:
Imnovid 1 mg hård kapsel: Mørkeblå, uigennemsigtig hætte og gul uigennemsigtig kapselunderdel, præget med ”POML1 mg”.
Imnovid 1 mg hard capsule: Dark blue opaque cap and yellow opaque body, with“POML 1 mg” written on them.
Imnovid 1 mg hård kapsel: Mørkeblå, uigennemsigtig overdel og gul, uigennemsigtig underdel, præget med ”POML” med hvidt blæk og ”1 mg” med sort blæk, størrelse 4, hård gelatinekapsel.
Imnovid 1 mg hard capsule: Dark blue opaque cap and yellow opaque body, imprinted “POML” in white ink and “1 mg” in black ink, size 4, hard gelatin capsule.
Imnovid 1 mg hårde kapsler Imnovid 2 mg hårde kapsler Imnovid 3 mg hårde kapsler Imnovid 4 mg hårde kapsler pomalidomid
Imnovid 1 mg hard capsules Imnovid 2 mg hard capsules Imnovid 3 mg hard capsules Imnovid 4 mg hard capsules Pomalidomide
Imnovid 2 mg hård kapsel: Mørkeblå, uigennemsigtig hætte og orange uigennemsigtig kapselunderdel, præget med ”POML2 mg”.
Imnovid 2 mg hard capsule: Dark blue opaque cap and orange opaque body, with“POML 2 mg” written on them.
Imnovid 2 mg hård kapsel: Mørkeblå, uigennemsigtig overdel og orange, uigennemsigtig underdel, præget med ”POML 2 mg” med hvidt blæk, størrelse 2, hård gelatinekapsel.
Imnovid 2 mg hard capsule: Dark blue opaque cap and orange opaque body, imprinted “POML 2 mg” in white ink, size 2, hard gelatin capsule.
Imnovid 3 mg hård kapsel: Mørkeblå, uigennemsigtig hætte og grøn uigennemsigtig kapselunderdel, præget med ”POML3 mg”.
Imnovid 3 mg hard capsule: Dark blue opaque cap and green opaque body, with“POML 3 mg” written on them.
Imnovid 3 mg hård kapsel: Mørkeblå, uigennemsigtig overdel og grøn, uigennemsigtig underdel, præget med ”POML 3 mg” med hvidt blæk, størrelse 2, hård gelatinekapsel.
Imnovid 3 mg hard capsule: Dark blue opaque cap and green opaque body, imprinted, “POML 3 mg” in white ink, size 2, hard gelatin capsule.
Imnovid 4 mg hård kapsel: Mørkeblå, uigennemsigtig hætte og blå uigennemsigtig kapselunderdel, præget med ”POML4 mg”.
Imnovid 4 mg hard capsule: Dark blue opaque cap and blue opaque body, with“POML 4 mg” written on them.
Imnovid 4 mg hård kapsel: Mørkeblå, uigennemsigtig overdel og blå, uigennemsigtig underdel, præget med ”POML 4 mg” med hvidt blæk, størrelse 2, hård gelatinekapsel.
Imnovid 4 mg hard capsule: Dark blue opaque cap and blue opaque body, imprinted “POML 4 mg” in white ink, size 2, hard gelatin capsule.
Imnovid bør ikke anvendes til børn og unge mennesker under 18 år.
Imnovid is not recommended for use in children and young people under 18 years.
Imnovid bør tages på cirka samme tidspunkt hver dag.
Imnovid should be taken at the same time each day.
Imnovid er et lægemiddel til behandling af kræft, der indeholder det aktive stof pomalidomid.
Imnovid is an anticancer medicine that contains the active substance pomalidomide.
Imnovid findes som kapsler (1, 2, 3 og 4 mg) og tages i 4-ugers behandlingsperioder.
Imnovid is available as capsules (1, 2, 3 and 4 mg) and is taken in 4-week treatment cycles.
Imnovid og dexamethason tages i behandlingscyklusser.
Imnovid and dexamethasone are taken in treatment cycles.
Imnovid plus lavdosis dexamethason var mere effektivt end højdosis dexamethason alene til at forsinke udviklingen af multipelt myelom: I gennemsnit gik der 16 uger, før sygdommen blev værre hos patienter, der tog Imnovid plus lavdosis dexamethason, sammenlignet med 8 uger hos de patienter, der tog højdosis dexamethason.
Imnovid plus low-dose dexamethasone was more effective than high-dose dexamethasone alone at delaying the progression of multiple myeloma: on average, it took 16 weeks before the disease got worse in patients taking Imnovid plus low-dose dexamethasone, compared with 8 weeks in those taking high-dose dexamethasone.
Imnovid påvirker i mindre eller moderat grad evnen til at føre motorkøretøj og betjene maskiner.
Imnovid has minor or moderate influence on the ability to drive and use machines.
Imnovid tages sammen med et andet lægemiddel, der kaldes dexamethason.
Imnovid is taken in combination with another medicine called dexamethasone.
Imnovid udskilles i sæden hos mennesker.
Imnovid passes into human semen.
Imnovid1 pomalidomid
Imnovid1 pomalidomide
IMP og VIM metallo-betalaktamaser eller KPC typer), skønt disse er sjældne.
IMP and VIM metallo-beta-lactamases or KPC types), though these are rare.
IMPACT 2.
2 (2.6%)
IMPACT IMPACT 2*
IMPACT 2
Imperiøs defækationstrang Fedt-/olieagtig afføring Flatulens
Faecal urgency Fatty/oily stool Flatulence Liquid stools Oily evacuation
Imperiøs defækationstrang Fedt-/olieholdig afføring Olieagtige udtømninger Flatulens
Fatty oily stool Oily evacuation Flatulence
Imperiøs vandladning
Menstrual disorder
Imperiøs vandladning
Urinary urgency
Imperiøs vandladningstrang
Urinary urgency
Impetigo-læsioner > 10 i antal og med et totalt overfladeareal på mere end 100 cm2.
Impetiginous lesions >10 in number and exceeding 100 cm2 in total surface area.
Implantat
Contraceptive implant
Implantatet er en uigennemsigtig, off-white membran med chondrocytter, leveret i 18 ml farveløs opløsning i en skål.
The implant is an opaque, off-white membrane, seeded with chondrocytes, supplied in 18 ml of colourless solution in a dish.
Implantatet er fremstillet af et materiale, der opløses i løbet af adskillige måneder, mens det gradvist frigiver dexamethason.
The implant is made of a material that dissolves over several months while gradually releasing the dexamethasone.
Implantatet gives som en injektion under huden ved hjælp af et kateter og en kanyle (subkutant).
The implant is given as injection under your skin using a catheter tube and needle (subcutaneous use).
Implantatet indeholder 16 mg afamelanotid.
The implant contains 16 mg of afamelanotide.
Implantatet ska indgives subkutant mellem hundens skulderblade.
The implant should be administered subcutaneously between the shoulder blades of the dog.
implantation
(Invented) name
Implantation Pulver (eptotermin alfa): hætteglas (glas/alu); Pulver (carmellose): hætteglas (glas/alu)
powder (carmellose): vial (glass/alu)
implantation,
implantation
Implantation:
Implantation
Implantationen bør følges op af en passende genoptræningsplan i ca. et år som anbefalet af lægen (se afsnit 4.4).
The implantation should be followed by an appropriate rehabilitation schedule for approximately one year, as recommended by the physician (see section 4.4).
Implantationsmatrix.
Implantation matrix.
implanteret andre steder end lumbal rygsøjle anvendt ved andre kirurgiske teknikker end lumbal interkorporal fusion
implanted at locations other than lumbar spine used in surgical techniques other than lumbar interbody fusion
Implementerbart insulinpumpesystem: Manualer til læger
Implantable Insulin Pump system: Physician Manuals
Implementeringen af nationale foranstaltninger for at vurdere effektiviteten og overholdelsen af PPP.
The set-up of national measures to assess the effectiveness of and compliance with the PPP.
Impotens
ALT increased
impotens inflammationer
impotence inflammations
impotens, blødning fra skeden, udeblivende eller kraftige menstruationer, irritation af skeden, brystsmerter
exual impotence, vaginal bleeding, absent or heavy menstrual periods, vaginal irritation, breast pain,
Impotens, brystforstørrelse hos mænd, symptomer på overgangsalder
erectile dysfunction; breast enlargement in men; menopausal symptoms
impotens, større bryster søvnproblemer, søvnighed, depression, angst, unormale drømme, nedgang i seksuallyst.
erectile dysfunction, enlargement of breasts sleeping problems, sleepiness, depression, anxiety, abnormal dreams, decrease in sexual drive
impotens, unormalt kraftig menstruation eller manglende menstruation;
impotence, abnormally heavy or extended menstrual flow or a lack of menstruation;
impotens; inflammationer.
impotence; inflammations.
Impotensam, gynækomastiam
Impotenceam, gynaecomastiaam